PortalPublikationenPhysiological aspects of cardiac tissue engineering.

Physiological aspects of cardiac tissue engineering.

Standard

Physiological aspects of cardiac tissue engineering. / Eschenhagen, Thomas; Eder, Alexandra; Vollert, Ingra; Hansen, Arne.

in: AM J PHYSIOL-HEART C, Jahrgang 303, Nr. 2, 2, 2012, S. 133-143.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Eschenhagen, T, Eder, A, Vollert, I & Hansen, A 2012, 'Physiological aspects of cardiac tissue engineering.', AM J PHYSIOL-HEART C, Jg. 303, Nr. 2, 2, S. 133-143. <http://www.ncbi.nlm.nih.gov/pubmed/22582087?dopt=Citation>

APA

Eschenhagen, T., Eder, A., Vollert, I., & Hansen, A. (2012). Physiological aspects of cardiac tissue engineering. AM J PHYSIOL-HEART C, 303(2), 133-143. [2]. http://www.ncbi.nlm.nih.gov/pubmed/22582087?dopt=Citation

Vancouver

Eschenhagen T, Eder A, Vollert I, Hansen A. Physiological aspects of cardiac tissue engineering. AM J PHYSIOL-HEART C. 2012;303(2):133-143. 2.

Bibtex

@article{99ebaf41877e48a385d0c7458aee44ff,
title = "Physiological aspects of cardiac tissue engineering.",
abstract = "Cardiac tissue engineering aims at repairing the diseased heart and developing cardiac tissues for basic research and predictive toxicology applications. Since the first description of engineered heart tissue 15 years ago, major development steps were directed toward these three goals. Technical innovations led to improved three-dimensional cardiac tissue structure and near physiological contractile force development. Automation and standardization allow medium throughput screening. Larger constructs composed of many small engineered heart tissues or stacked cell sheet tissues were tested for cardiac repair and were associated with functional improvements in rats. Whether these approaches can be simply transferred to larger animals or the human patients remains to be tested. The availability of an unrestricted human cardiac myocyte cell source from human embryonic stem cells or human-induced pluripotent stem cells is a major breakthrough. This review summarizes current tissue engineering techniques with their strengths and limitations and possible future applications.",
keywords = "Animals, Humans, Mice, Rats, Tissue Engineering/*methods, Heart/*physiology, Embryonic Stem Cells/physiology, Heart Diseases/*therapy, Pluripotent Stem Cells/physiology, Animals, Humans, Mice, Rats, Tissue Engineering/*methods, Heart/*physiology, Embryonic Stem Cells/physiology, Heart Diseases/*therapy, Pluripotent Stem Cells/physiology",
author = "Thomas Eschenhagen and Alexandra Eder and Ingra Vollert and Arne Hansen",
year = "2012",
language = "English",
volume = "303",
pages = "133--143",
journal = "AM J PHYSIOL-HEART C",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "2",

}

RIS

TY - JOUR

T1 - Physiological aspects of cardiac tissue engineering.

AU - Eschenhagen, Thomas

AU - Eder, Alexandra

AU - Vollert, Ingra

AU - Hansen, Arne

PY - 2012

Y1 - 2012

N2 - Cardiac tissue engineering aims at repairing the diseased heart and developing cardiac tissues for basic research and predictive toxicology applications. Since the first description of engineered heart tissue 15 years ago, major development steps were directed toward these three goals. Technical innovations led to improved three-dimensional cardiac tissue structure and near physiological contractile force development. Automation and standardization allow medium throughput screening. Larger constructs composed of many small engineered heart tissues or stacked cell sheet tissues were tested for cardiac repair and were associated with functional improvements in rats. Whether these approaches can be simply transferred to larger animals or the human patients remains to be tested. The availability of an unrestricted human cardiac myocyte cell source from human embryonic stem cells or human-induced pluripotent stem cells is a major breakthrough. This review summarizes current tissue engineering techniques with their strengths and limitations and possible future applications.

AB - Cardiac tissue engineering aims at repairing the diseased heart and developing cardiac tissues for basic research and predictive toxicology applications. Since the first description of engineered heart tissue 15 years ago, major development steps were directed toward these three goals. Technical innovations led to improved three-dimensional cardiac tissue structure and near physiological contractile force development. Automation and standardization allow medium throughput screening. Larger constructs composed of many small engineered heart tissues or stacked cell sheet tissues were tested for cardiac repair and were associated with functional improvements in rats. Whether these approaches can be simply transferred to larger animals or the human patients remains to be tested. The availability of an unrestricted human cardiac myocyte cell source from human embryonic stem cells or human-induced pluripotent stem cells is a major breakthrough. This review summarizes current tissue engineering techniques with their strengths and limitations and possible future applications.

KW - Animals

KW - Humans

KW - Mice

KW - Rats

KW - Tissue Engineering/methods

KW - Heart/physiology

KW - Embryonic Stem Cells/physiology

KW - Heart Diseases/therapy

KW - Pluripotent Stem Cells/physiology

KW - Animals

KW - Humans

KW - Mice

KW - Rats

KW - Tissue Engineering/methods

KW - Heart/physiology

KW - Embryonic Stem Cells/physiology

KW - Heart Diseases/therapy

KW - Pluripotent Stem Cells/physiology

M3 - SCORING: Journal article

VL - 303

SP - 133

EP - 143

JO - AM J PHYSIOL-HEART C

JF - AM J PHYSIOL-HEART C

SN - 0363-6135

IS - 2

M1 - 2

ER -